{"title":"Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?","authors":"Winston Dunn, Naim Alkhouri","doi":"10.1007/s11894-025-01002-5","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatohepatitis with significant fibrosis is the aggressive form of steatotic liver disease that can progress to cirrhosis and its complications. Resmetirom is a liver-directed thyroid hormone receptor beta agonist that recently received accelerated approval by the FDA based on the results of the MAESTRO trial that demonstrated reasonable safety and efficacy in achieving both MASH resolution and fibrosis regression based on histological assessment. In this review, we discuss the resmetirom clinical development program, the use of noninvasive tests to select and monitor patients for treatment, and different aspects of the utility of resmetirom in the real world.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"53"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gastroenterology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11894-025-01002-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Metabolic dysfunction-associated steatohepatitis with significant fibrosis is the aggressive form of steatotic liver disease that can progress to cirrhosis and its complications. Resmetirom is a liver-directed thyroid hormone receptor beta agonist that recently received accelerated approval by the FDA based on the results of the MAESTRO trial that demonstrated reasonable safety and efficacy in achieving both MASH resolution and fibrosis regression based on histological assessment. In this review, we discuss the resmetirom clinical development program, the use of noninvasive tests to select and monitor patients for treatment, and different aspects of the utility of resmetirom in the real world.
期刊介绍:
As the field of gastroenterology and hepatology rapidly evolves, the wealth of published literature can be overwhelming. The aim of the journal is to help readers stay abreast of such advances by offering authoritative, systematic reviews by leading experts. We accomplish this aim by appointing Section Editors who invite international experts to contribute review articles that highlight recent developments and important papers published in the past year. Major topics in gastroenterology are covered, including pediatric gastroenterology, neuromuscular disorders, infections, nutrition, and inflammatory bowel disease. These reviews provide clear, insightful summaries of expert perspectives relevant to clinical practice. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.